UDEMY Pharmacovigilance Course

5.13 GB | 37min 56s | mp4 | 1280X720 | 16:9
Genre:eLearning |Language:English

Files Included :
1 About Drug Discovery Part 1.mp4 (42.66 MB)
2 History of Drug Discovery Part 2.mp4 (101.89 MB)
3 CRO and Sponsor Responsibilities Part 3.mp4 (58.24 MB)
4 Monitor Responsibilities Part 4.mp4 (155.27 MB)
5 History of Clinical Research Part 5.mp4 (272.64 MB)
54 WHO and ICSR Key Points on Signal Detection Part 1.mp4 (85.21 MB)
55 Risk Managemeny Part 2.mp4 (31.99 MB)
56 Coding in Pharmacovigilance Part 3.mp4 (37.3 MB)
57 Drug Dictionary Part 4.mp4 (193.11 MB)
58 Coding Using MedDRA Part 5.mp4 (65.14 MB)
59 General Considerations Part 1.mp4 (53.93 MB)
60 Safety Database Part 2.mp4 (163.48 MB)
61 ARISg & ARGUS Part 3.mp4 (41.18 MB)
62 Data Assessment Duplicate Check Part 4.mp4 (153.61 MB)
63 Assessment of Class Once Saved in ARISg Part 5.mp4 (44.44 MB)
64 Mandatory Field For Newcase Creation Part 6.mp4 (137.35 MB)
65 Duplicate Check Part 1.mp4 (24.98 MB)
66 Cases Part 2.mp4 (134.1 MB)
67 Product Table Part 3.mp4 (127.54 MB)
68 Product Table Part 1.mp4 (85.41 MB)
69 Worklist Part 2.mp4 (182.25 MB)
10 Lifecycle of Drug and Pharmacovigilance Part 5.mp4 (26.22 MB)
11 Need of Pharmacovigilance Even After Clinical Trials Part 6.mp4 (50.13 MB)
12 Do Pharmacovigilance Needed in Every Country Part 7.mp4 (20.33 MB)
13 Term & Definitions Part 8.mp4 (120.3 MB)
14 Term & Definitions Part 9.mp4 (36.39 MB)
15 Partners in Pharmacovigilance Part 10.mp4 (30.25 MB)
16 Drug Regulatory Authorities Part 11.mp4 (6.13 MB)
17 Pharmacovigilance Help & Rational Part 12.mp4 (43.1 MB)
18 What to Report Part 13.mp4 (14.74 MB)
19 History of Pharmacovigilance Evolution Part 14.mp4 (92.84 MB)
6 Problems Due to Inadequate PV System Part 1.mp4 (56.89 MB)
7 Active Ingredients Withdrawn Part 2.mp4 (21.76 MB)
8 Pharmacovigilance Definition Part 3.mp4 (46.64 MB)
9 Pharmacovigilance Aim & Responsbilites Part 4.mp4 (28.59 MB)
20 Principle Part 1.mp4 (199.08 MB)
21 Principle Part 2.mp4 (46.46 MB)
22 Sources of AE Reports Part 3.mp4 (23.46 MB)
23 Sources of AE Reports Part 4.mp4 (52.6 MB)
24 Timeline for ADR Reporting Part 1.mp4 (61.24 MB)
25 ICSR Report Part 2.mp4 (56.85 MB)
26 Form FDA Part 3.mp4 (27.53 MB)
27 ICSR Case Processing Workflow Part 4.mp4 (15.88 MB)
28 Receive Case Report Sources Part 5.mp4 (16.4 MB)
29 Safety Data Processing Part 6.mp4 (29.53 MB)
30 Receive Case Report Sources Part 7.mp4 (45.62 MB)
31 Sources of ICRSs Part 1.mp4 (46.69 MB)
32 Validity Criteria Part 2.mp4 (66.67 MB)
33 Steps in Triage Activity Part 3.mp4 (6.52 MB)
34 Steps in Triage Activity Part 4.mp4 (138.18 MB)
35 Regulatory Timelines Part 5.mp4 (26.78 MB)
36 Aggregate Reporting Part 6.mp4 (173.33 MB)
37 Narrative Writing Part 1.mp4 (76.82 MB)
38 Structure of A Narrative Part 2.mp4 (140.63 MB)
39 Example Part 3.mp4 (87.86 MB)
40 Introductory Paragraph Part 4.mp4 (29.01 MB)
41 Follow Up Narrative Part 5.mp4 (29.03 MB)
42 Follow Up Narrative Part 6.mp4 (4.68 MB)
43 Narrative Writing Part 7.mp4 (38.98 MB)
44 Why Need Regulation Part 8.mp4 (105.21 MB)
45 Labelling of Drugs Part 1.mp4 (74.08 MB)
46 Highlights for a Fictitious of Drug Part 2.mp4 (49.83 MB)
47 Example Part 3.mp4 (94.46 MB)
48 medDRA Process Flow Part 4.mp4 (49.87 MB)
49 Re-Assessment of Follow Up Part 1.mp4 (73.17 MB)
50 Example Part 2.mp4 (170.95 MB)
51 Signal Management Part 1.mp4 (96.36 MB)
52 Signal Management Part 2.mp4 (184.37 MB)
53 Risk Management Part 3.mp4 (124.58 MB)]
Screenshot

We need your support!
Make a donation to help us stay online
        
Bitcoin (BTC)
bc1q08g9d22cxkawsjlf8etuek2pc9n2a3hs4cdrld
	
Bitcoin Cash (BCH)
qqvwexzhvgauxq2apgc4j0ewvcak6hh6lsnzmvtkem

Ethereum (ETH)
0xb55513D2c91A6e3c497621644ec99e206CDaf239

Litecoin (LTC)
ltc1qt6g2trfv9tjs4qj68sqc4uf0ukvc9jpnsyt59u

USDT (ERC20)
0xb55513D2c91A6e3c497621644ec99e206CDaf239

USDT (TRC20)
TYdPNrz7v1P9riWBWZ317oBgJueheGjATm